Corbus Pharmaceuticals Holdings Inc
CRBP9.315USD
+0.005+0.05%
Market hours （ET）Quotes delayed by 15 min
113.95MMarket Cap
LossP/E TTM
More Details of Corbus Pharmaceuticals Holdings Inc Company
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Company Info
Ticker SymbolCRBP
Company nameCorbus Pharmaceuticals Holdings Inc
IPO dateOct 24, 2014
CEODr. Yuval Cohen, Ph.D.
Number of employees28
Security typeOrdinary Share
Fiscal year-endOct 24
Address500 River Ridge Drive
CityNORWOOD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02062
Phone16179630103
Websitehttps://www.corbuspharma.com/
Ticker SymbolCRBP
IPO dateOct 24, 2014
CEODr. Yuval Cohen, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
-52.68%
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
-77.23%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
Dr. Anne Altmeyer, Ph.D.
Dr. Anne Altmeyer, Ph.D.
Independent Director
Independent Director
3.41K
--
Dr. Ian Hodgson
Dr. Ian Hodgson
Chief Operating Officer
Chief Operating Officer
1.23K
--
Dr. John Kenneth Jenkins, M.D.
Dr. John Kenneth Jenkins, M.D.
Independent Director
Independent Director
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
-52.68%
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
-77.23%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jul 28
Updated: Mon, Jul 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
19.41%
OrbiMed Advisors, LLC
9.58%
Octagon Capital Advisors LP
9.11%
BlackRock Institutional Trust Company, N.A.
6.46%
The Vanguard Group, Inc.
4.90%
Other
50.54%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
19.41%
OrbiMed Advisors, LLC
9.58%
Octagon Capital Advisors LP
9.11%
BlackRock Institutional Trust Company, N.A.
6.46%
The Vanguard Group, Inc.
4.90%
Other
50.54%
Shareholder Types
Shareholders
Proportion
Hedge Fund
49.09%
Investment Advisor
16.03%
Investment Advisor/Hedge Fund
12.17%
Private Equity
9.58%
Venture Capital
3.52%
Bank and Trust
1.74%
Research Firm
1.40%
Individual Investor
0.61%
Pension Fund
0.07%
Other
5.79%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
246
11.50M
94.01%
-3.45M
2025Q1
251
11.62M
94.98%
-3.51M
2024Q4
256
12.27M
100.79%
-2.94M
2024Q3
245
12.92M
107.22%
+703.14K
2024Q2
212
12.40M
115.98%
+3.38M
2024Q1
167
10.08M
102.86%
+5.32M
2023Q4
134
960.97K
21.74%
-489.88K
2023Q3
143
765.13K
17.31%
-695.27K
2023Q2
165
756.43K
17.12%
-730.85K
2023Q1
205
764.30K
18.94%
-373.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cormorant Asset Management, LP
2.38M
19.41%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.17M
9.58%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
1.11M
9.11%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
790.90K
6.46%
-27.90K
-3.41%
Mar 31, 2025
The Vanguard Group, Inc.
672.06K
5.49%
+12.86K
+1.95%
Mar 31, 2025
Prosight Capital
575.14K
4.7%
+305.14K
+113.01%
Mar 31, 2025
RA Capital Management, LP
430.18K
3.52%
+430.18K
--
Feb 02, 2024
Paradigm BioCapital Advisors LP
399.66K
3.27%
+399.66K
--
Jan 26, 2024
Renaissance Technologies LLC
345.20K
2.82%
+206.10K
+148.17%
Mar 31, 2025
Exome Asset Management LLC
289.69K
2.37%
+289.69K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Pacer WealthShield ETF
0%
Harbor Health Care ETF
0%
ProShares Hedge Replication ETF
0%
Tema Oncology ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Vanguard US Momentum Factor ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Pacer WealthShield ETF
Proportion0%
Harbor Health Care ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Date
Type
Ratio
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
